NCT05986851View on ClinicalTrials.gov

Azeliragon in MGMT Unmethylated Glioblastoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 12, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

June 30, 2025

Conditions
Glioblastoma
Interventions
DRUG

Azeliragon

Oral capsule

Trial Locations (8)

10021

Lenox Hill Hospital, New York

33176

Miami Cancer Institute - Baptist Health, Miami

48073

Corewell Health, Royal Oak

63110

Washington University in St. Louis, St Louis

73104

The University of Oklahoma Health Science Center, Oklahoma City

80045

University of Colorado Anschutz Medical Campus, Aurora

84112

University of Utah Health Huntsman Cancer Center, Salt Lake City

98109

University of Washington, Seattle

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

Cantex Pharmaceuticals

INDUSTRY

NCT05986851 - Azeliragon in MGMT Unmethylated Glioblastoma | Biotech Hunter | Biotech Hunter